These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 21705450)

  • 1. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
    Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
    Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
    Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
    J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer.
    Qian F; Gnjatic S; Jäger E; Santiago D; Jungbluth A; Grande C; Schneider S; Keitz B; Driscoll D; Ritter G; Lele S; Sood A; Old LJ; Odunsi K
    Cancer Immun; 2004 Nov; 4():12. PubMed ID: 15521719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles.
    Butler MO; Ansén S; Tanaka M; Imataki O; Berezovskaya A; Mooney MM; Metzler G; Milstein MI; Nadler LM; Hirano N
    Int Immunol; 2010 Nov; 22(11):863-73. PubMed ID: 21059769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of multiple HLA-DR-restricted epitopes of the tumor-associated antigen CAMEL by CD4+ Th1/Th2 lymphocytes.
    Slager EH; van der Minne CE; Krüse M; Krueger DD; Griffioen M; Osanto S
    J Immunol; 2004 Apr; 172(8):5095-102. PubMed ID: 15067093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.
    Chikamatsu K; Sakakura K; Takahashi G; Okamoto A; Furuya N; Whiteside TL; DeLeo AB; Masuyama K
    Cancer Immunol Immunother; 2009 Sep; 58(9):1441-8. PubMed ID: 19184003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
    Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
    Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Engineered Exosomes Expressing HLA and Costimulatory Molecules to Generate Antigen-specific CD8+ T Cells for Adoptive Cell Therapy.
    Kim S; Sohn HJ; Lee HJ; Sohn DH; Hyun SJ; Cho HI; Kim TG
    J Immunother; 2017 Apr; 40(3):83-93. PubMed ID: 28099196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell-based immunotherapy.
    Schultz ES; Schuler-Thurner B; Stroobant V; Jenne L; Berger TG; Thielemanns K; van der Bruggen P; Schuler G
    J Immunol; 2004 Jan; 172(2):1304-10. PubMed ID: 14707109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scanning the HIV genome for CD4+ T cell epitopes restricted to HLA-DP4, the most prevalent HLA class II molecule.
    Cohen WM; Pouvelle-Moratille S; Wang XF; Farci S; Munier G; Charron D; Ménez A; Busson M; Maillère B
    J Immunol; 2006 May; 176(9):5401-8. PubMed ID: 16622007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
    Zeng G; Wang X; Robbins PF; Rosenberg SA; Wang RF
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3964-9. PubMed ID: 11259659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients.
    Wang XF; Kerzerho J; Adotevi O; Nuyttens H; Badoual C; Munier G; Oudard S; Tu S; Tartour E; Maillère B
    J Immunol; 2008 Jul; 181(1):431-9. PubMed ID: 18566409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 30-kDa and 38-kDa antigens from Mycobacterium tuberculosis induce partial maturation of human dendritic cells shifting CD4(+) T cell responses towards IL-4 production.
    Heuer M; Behlich AS; Lee JS; Ribechini E; Jo EK; Lutz MB
    BMC Immunol; 2013 Oct; 14():48. PubMed ID: 24089996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
    Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
    Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
    Tatsumi T; Kierstead LS; Ranieri E; Gesualdo L; Schena FP; Finke JH; Bukowski RM; Mueller-Berghaus J; Kirkwood JM; Kwok WW; Storkus WJ
    J Exp Med; 2002 Sep; 196(5):619-28. PubMed ID: 12208877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
    Atanackovic D; Altorki NK; Stockert E; Williamson B; Jungbluth AA; Ritter E; Santiago D; Ferrara CA; Matsuo M; Selvakumar A; Dupont B; Chen YT; Hoffman EW; Ritter G; Old LJ; Gnjatic S
    J Immunol; 2004 Mar; 172(5):3289-96. PubMed ID: 14978137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation.
    Tao X; Constant S; Jorritsma P; Bottomly K
    J Immunol; 1997 Dec; 159(12):5956-63. PubMed ID: 9550393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a humanized HLA-A2.1/DP4 transgenic mouse model and the use of this model to map HLA-DP4-restricted epitopes of HBV envelope protein.
    Ru Z; Xiao W; Pajot A; Kou Z; Sun S; Maillere B; Zhao G; Ojcius DM; Lone YC; Zhou Y
    PLoS One; 2012; 7(3):e32247. PubMed ID: 22403638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Analysis of CD4
    Hyun YS; Jo HA; Lee YH; Kim SM; Baek IC; Sohn HJ; Cho HI; Kim TG
    Front Immunol; 2020; 11():602014. PubMed ID: 33658991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.